Liraglutide in Acute Minor Ischemic Stroke or High-risk Transient Ischemic Attack Patients With Type 2 Diabetes Mellitus

Summary

The purpose of this study is to assess the safety and efficacy of glucagon-like peptide-1 (GLP-1) analogue liraglutide in the treatment of acute minor stroke (National Institute of Health stroke scale, NIHSS ≤ 3) or high-risk transient ischemic attack (TIA) (ABCD2 score ≥ 4 ) patients with type 2 diabetes mellitus.

Timeline

Start

2019-06-25

Primary completion

2023-12

Completion

2024-06

Publications

• Lu L, Yang B, Wang Y, Zhu C, Liu Z, Li F, Yang S, Liu Y, Yang Y, Liu X, Huang L, Xu A, Zhu H. Liraglutide and Recurrent Stroke by Baseline Insulin Resistance: A Post Hoc Analysis of the LAMP Trial. Stroke. 2026 Jul;57(7):1960-1970. doi: 10.1161/STROKEAHA.125.056010. Epub 2026 May 18.
• Zhu H, Yang B, Lu L, Li Y, Sui R, Liu K, Tan S, Wang L, Qiu J, Zhong J, Wei T, Bei Y, Huang J, Zhang S, Ji Y, Wu W, Li Y, Huang Y, Chen Y, Huang X, Zeng G, Zhang Y, Huang L, Li H, Wang X, Wang Y, Xu A; LAMP Investigators. Liraglutide in Acute Minor Ischemic Stroke or High-Risk Transient Ischemic Attack With Type 2 Diabetes: The LAMP Randomized Clinical Trial. JAMA Intern Med. 2026 Jan 1;186(1):46-54. doi: 10.1001/jamainternmed.2025.5684.

Drugs

Indications